HUP0204394A2 - Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same - Google Patents

Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same

Info

Publication number
HUP0204394A2
HUP0204394A2 HU0204394A HUP0204394A HUP0204394A2 HU P0204394 A2 HUP0204394 A2 HU P0204394A2 HU 0204394 A HU0204394 A HU 0204394A HU P0204394 A HUP0204394 A HU P0204394A HU P0204394 A2 HUP0204394 A2 HU P0204394A2
Authority
HU
Hungary
Prior art keywords
compounds
preparation
pharmaceutical compositions
compositions containing
containing same
Prior art date
Application number
HU0204394A
Other languages
English (en)
Inventor
Marco Baroni
Bernard Bourrie
Rosanna Cardamone
Pierre Casellas
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of HUP0204394A2 publication Critical patent/HUP0204394A2/hu
Publication of HUP0204394A3 publication Critical patent/HUP0204394A3/hu
Publication of HU224815B1 publication Critical patent/HU224815B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A találmány (I) általános képletű vegyületekre, a képletben R1jelentése hidrogén- vagy halogénatom vagy trifluormetilcsoport; R2 ésR3 jelentése egymástól függetlenül hidrogénatom vagy metilcsoport; nés n' értéke egymástól függetlenül 0 vagy 1; * jelenti a kapcsolódáshelyét; A jelentése -N= vagy -CH= csoport; X jelentése kén- vagyoxigénatom; R4 és R5 jelentése egymástól függetlenül hidrogénatom vagy1-6 szénatomos alkilcsoport; és a vegyületek sóira vagy szolvátjaira,a vegyületek előállítására alkalmas eljárásra, valamint a vegyületekettartalmazó gyógyászati készítményekre vonatkozik. Ó
HU0204394A 2000-01-06 2000-12-29 Tetrahydropyridines, process for their preparation, pharmaceutical compositions containing them and use thereof HU224815B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0000113A FR2803593B1 (fr) 2000-01-06 2000-01-06 Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
PCT/FR2000/003741 WO2001049684A1 (fr) 2000-01-06 2000-12-29 Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Publications (3)

Publication Number Publication Date
HUP0204394A2 true HUP0204394A2 (en) 2003-05-28
HUP0204394A3 HUP0204394A3 (en) 2005-04-28
HU224815B1 HU224815B1 (en) 2006-02-28

Family

ID=8845654

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204394A HU224815B1 (en) 2000-01-06 2000-12-29 Tetrahydropyridines, process for their preparation, pharmaceutical compositions containing them and use thereof

Country Status (28)

Country Link
US (1) US6689797B2 (hu)
EP (1) EP1248785B1 (hu)
JP (1) JP2004501861A (hu)
KR (1) KR100755103B1 (hu)
CN (1) CN1200939C (hu)
AT (1) ATE297918T1 (hu)
AU (1) AU782650B2 (hu)
BR (1) BR0016921A (hu)
CA (1) CA2395969C (hu)
CZ (1) CZ300658B6 (hu)
DE (1) DE60020885T2 (hu)
EA (1) EA004858B1 (hu)
EE (1) EE04814B1 (hu)
FR (1) FR2803593B1 (hu)
HK (1) HK1050532A1 (hu)
HU (1) HU224815B1 (hu)
IL (1) IL150605A0 (hu)
IS (1) IS2472B (hu)
ME (1) MEP21808A (hu)
MX (1) MXPA02006709A (hu)
NO (1) NO322598B1 (hu)
NZ (1) NZ519723A (hu)
PL (1) PL202761B1 (hu)
RS (1) RS50432B (hu)
SK (1) SK285557B6 (hu)
UA (1) UA72017C2 (hu)
WO (1) WO2001049684A1 (hu)
ZA (1) ZA200205223B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU778306B2 (en) * 1999-10-22 2004-11-25 Sanofi-Aventis Phenyl- and pyridyl-tetrahydro-pyridines having TNF inhibiting activity
FR2831166B1 (fr) * 2001-10-18 2004-02-27 Sanofi Synthelabo Aralkyl-tetrahydro-pyridines, leur preparation et compositions pharmaceutiques les contenant
FR2832405B1 (fr) * 2001-11-19 2004-12-10 Sanofi Synthelabo Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
JP5550352B2 (ja) * 2007-03-15 2014-07-16 ノバルティス アーゲー 有機化合物およびその使用
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
FR2953836B1 (fr) * 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
US11129746B2 (en) 2010-06-23 2021-09-28 Dental Choice Holdings Llc Method and oral appliance for improving air intake and reducing bruxism
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
CA3085388A1 (en) 2017-12-12 2019-06-20 Queen's University At Kingston Compounds and methods for inhibiting cyp26 enzymes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2060816C3 (de) * 1970-12-10 1980-09-04 Merck Patent Gmbh, 6100 Darmstadt 4-Phenylpiperidinderivate Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen enthaltend diese Verbindungen
US5273977A (en) * 1990-11-05 1993-12-28 Warner-Lambert Company Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
GB9604036D0 (en) * 1996-02-26 1996-04-24 Merck Sharp & Dohme Therapeutic agents
FR2751645B1 (fr) * 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
DE19826841A1 (de) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine

Also Published As

Publication number Publication date
WO2001049684A1 (fr) 2001-07-12
EA004858B1 (ru) 2004-08-26
IL150605A0 (en) 2003-02-12
CZ20022302A3 (cs) 2002-10-16
EP1248785B1 (fr) 2005-06-15
PL357082A1 (en) 2004-07-12
EA200200611A1 (ru) 2002-12-26
SK9622002A3 (en) 2003-03-04
SK285557B6 (sk) 2007-03-01
NO20023251D0 (no) 2002-07-04
PL202761B1 (pl) 2009-07-31
CN1433412A (zh) 2003-07-30
CA2395969C (en) 2009-05-19
CA2395969A1 (en) 2002-07-03
EE200200382A (et) 2003-12-15
EP1248785A1 (fr) 2002-10-16
UA72017C2 (en) 2005-01-17
ZA200205223B (en) 2004-01-26
KR20020063291A (ko) 2002-08-01
DE60020885D1 (de) 2005-07-21
EE04814B1 (et) 2007-04-16
AU3031101A (en) 2001-07-16
NZ519723A (en) 2005-08-26
MEP21808A (en) 2010-06-10
RS50432B (sr) 2009-12-31
NO322598B1 (no) 2006-10-30
AU782650B2 (en) 2005-08-18
US20030083347A1 (en) 2003-05-01
US6689797B2 (en) 2004-02-10
IS2472B (is) 2008-12-15
YU51302A (sh) 2005-06-10
ATE297918T1 (de) 2005-07-15
HK1050532A1 (en) 2003-06-27
JP2004501861A (ja) 2004-01-22
FR2803593A1 (fr) 2001-07-13
FR2803593B1 (fr) 2002-02-15
DE60020885T2 (de) 2006-05-11
HUP0204394A3 (en) 2005-04-28
KR100755103B1 (ko) 2007-09-04
HU224815B1 (en) 2006-02-28
CN1200939C (zh) 2005-05-11
IS6452A (is) 2002-06-28
MXPA02006709A (es) 2002-10-23
BR0016921A (pt) 2002-10-15
CZ300658B6 (cs) 2009-07-08
NO20023251L (no) 2002-09-06

Similar Documents

Publication Publication Date Title
HUP0302480A2 (hu) Piridinonszármazékok ateroszklerózis kezelésére, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények
HUP0203836A2 (hu) 1,3-Diszubsztituált pirrolidin-származékok alfa2-adrenerg-receptor antagonista hatással, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0401537A2 (hu) Tiohidantoin-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására
HUP0300922A2 (hu) Új vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
HUP0402507A2 (hu) N(fenilszulfonil)glicin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
HUP0204235A2 (hu) Helyettesített glutárimidek és felhasználásuk IL-12 termelés inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0402225A2 (hu) Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP9802937A2 (hu) Benzo[g]kinolin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
HUP0104188A2 (hu) Antranilsav- és tioantranilsav-N-aril-amidok, előállításuk és alkalmazásuk VEGF receptor tirozinkináz inhibítorokként
HUP0204410A2 (en) Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
HUP0401886A2 (hu) Kemokin receptor aktivitás modulátorokként alkalmazható piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP9700992A2 (hu) 3-(Piperid-4-il)-1,2-benzizoxazol- és 3-(piperazin-4-il)-1,2-benzizoxazol-származékok, eljárás előállításukra, valamint ezeket tartalmazó gyógyászati készítmények
HUP0204394A2 (en) Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
ATE83773T1 (de) 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a.
HUP0401235A2 (hu) 5-HT6 receptor affinitással rendelkező arilszulfonil-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HUP0204354A2 (hu) Új heterociklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0303045A2 (hu) Pirimidinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0402602A2 (hu) Eljárás echinokandin-származékok előállítására, ezek alkalmazása, ezeket tartalmazó gyógyszerkészítmények és intermedierek
DE3769563D1 (de) Neue derivate von 4,5-dihydro-oxazolen, verfahren zu ihrer herstellung und ihre verwendung.
HUP0401713A2 (hu) Aralkiltetrahidropiridinek, a vegyületek előállítása, és ilyen vegyületeket tartalmazó gyógyászati készítmények
HUP0402585A2 (hu) Új benzotiazin- benzotiadiazin-származékok, előállításuk, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
HUP0303676A2 (hu) Helyettesített 4-fenil-1-(1-fenil-ciklohexil)-1,2,3,6-tetrahidropiridinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE365162T1 (de) Tetrahydropyridyl-alkyl-heterozykle, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees